Manager TitleAgeSince
President - 2025-07-29
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/22 Issuer sale

Chief Technology Officer

280,373 0.1193%
3/29/22 Tax

Executive/Senior Manager

68,414 0.0293%
3/29/22 Tax

Controller/Auditor

965 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.8B
-2.54%+1.31%+54.27%+117.14% 1,135B
-1.42%+3.23%+38.56%+74.05% 635B
+0.16%+0.08%+25.29%+96.64% 505B
-0.31%+3.09%+44.14%+64.55% 378B
-1.34%-0.47%+66.04%+40.18% 358B
-0.68%+2.65%+22.98%+49.15% 295B
-1.20%+3.04%+2.33%+21.60% 266B
-1.79%+1.57%+50.56%+61.40% 237B
-0.73%-0.10%+29.02%+99.06% 193B
Average -0.98%+1.60%+37.02%+69.31% 444.85B
Weighted average by Cap. -1.35%+1.63%+41.02%+80.33%
Logo Endo International plc
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116